Interim Report, January - March 2007

-Net revenues amounted to MSEK 6.4 (50.3)
-The loss after tax was MSEK 37.9 (profit: 15.3)
-Earnings per share amounted to a loss of SEK 2.73 (profit: 1.15)

KEY EVENTS DURING THE FIRST QUARTER OF 2007
-Orexo strengthens organization - Christina Rångemark Åkerman appointed Head of Technology and Product Development
-FDA approves Orexo’s application (IND) to complete Phase III study program for the insomnia product Sublinox™ (OX 22)

KEY EVENTS AFTER THE CLOSE OF THE PERIOD
-On April 23, Orexo held its Annual General Meeting – the Board of Directors was re-elected
-Orexo receives patent approval for OX 17

For report in full format, see enclosed link to pdf.


For more information, please contact
Zsolt Lavotha, President & CEO, Tel: +46 (0)18-780 88 12, e-mail: zsolt.lavotha@orexo.se

Claes Wenthzel, Executive Vice President and CFO, Orexo AB
+46 (0)18 780 88 44, +46 (0)708-62 01 22, e-mail: claes.wenthzel@orexo.se